Trial reportLeukemia2014
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Open access · greenAbstract readClinical Trial, Phase IILetter
In one paragraph
Trial report in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 89 citations in OpenAlex.
- Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.Blood advances · 2023Trial
- Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.American journal of hematology · 2018Trial
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.American journal of hematology · 2015Trial
- The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review.Health science reports · 2025Article
- Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches.Frontiers in oncology · 2024Review
- A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia.Haematologica · 2023Review
- How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?Cancer drug resistance (Alhambra, Calif.) · 2023Review
- FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile.OncoTargets and therapy · 2023Review
- Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein.ACS medicinal chemistry letters · 2022Article
- The Role of Nutrition in Primary and Secondary Prevention of Cardiovascular Damage in Childhood Cancer Survivors.Nutrients · 2022Review
- Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic RatioJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- High-Risk Acute Myeloid Leukemia: A Pediatric Prospective.Biomedicines · 2022Review
- New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.International journal of molecular sciences · 2022Review
- A review of FLT3 inhibitors in acute myeloid leukemia.Blood reviews · 2022Review
- Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.American journal of hematology · 2022Article
- Treatment options for acute myeloid leukemia patients aged <60 years.Frontiers in oncology · 2022Review
- New Drugs Bringing New Challenges to AML: A Brief Review.Journal of personalized medicine · 2021Review
- Maintenance therapy forHaematologica · 2021Review
- Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy.Current oncology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
F RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C Arana YiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J E CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M LevisDivision of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.
S FaderlDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
E JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S O'BrienDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
D ThomasDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M BrandtDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K PratzDivision of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.
R LuthraDivision of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USJohns Hopkins University · USSidney Kimmel Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MNCATS NIH HHS UL1 TR001079NCI NIH HHS CA016672NCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsCytarabineHumansIdarubicinLeukemia, Myeloid, AcuteNiacinamidePhenylurea CompoundsSorafenibTreatment OutcomeCytarabineIdarubicinNiacinamidePhenylurea CompoundsSorafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.